Lilly Asia Ventures
Overview
Lilly Asia Ventures is a biomedical venture capital firm that invests in biopharmaceuticals, human therapeutics, medical devices, and diagnostics.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Abogen Biosciences | Aug 2021 | Series C | Lead |
| Profound | Jun 2022 | Series A Extension | Co-investor |
| MediTrust Health | Aug 2021 | Series C | Co-investor |
| Insilico Medicine | Jun 2025 | Series E | Co-investor |
| Alumis Inc | Mar 2024 | Series C | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Lilly Asia Ventures based?
Lilly Asia Ventures is headquartered in Hong Kong, Hong Kong.
When was Lilly Asia Ventures founded?
Lilly Asia Ventures was founded in 2008.
How many portfolio companies does Lilly Asia Ventures have?
Lilly Asia Ventures has 100 portfolio companies in Caplight's dataset.
What are some companies in Lilly Asia Ventures's portfolio?
Portfolio companies visible on Caplight include Abogen Biosciences, Profound, MediTrust Health, Insilico Medicine, Alumis Inc.
What was Lilly Asia Ventures's most recent investment shown here?
Lilly Asia Ventures's most recent investment in this portfolio sample was in Insilico Medicine in 2025.
What sectors does Lilly Asia Ventures focus on?
Lilly Asia Ventures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, FinTech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Enterprise Software, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Enterprise Software, Frontier & Industrial Tech.
What company stages does Lilly Asia Ventures focus on?
Lilly Asia Ventures typically invests at the MultiStage stage.
What is Lilly Asia Ventures's AUM?
Lilly Asia Ventures's assets under management are estimated between $4.5B and $4.5B.